Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations

Author:

Garcia Simone12,Ramos Carolina O.1,Senra Juliana F. V.1,Vilas-Boas Fabio3,Rodrigues Maurício M.4,Campos-de-Carvalho Antonio C.2,Ribeiro-dos-Santos Ricardo1,Soares Milena B. P.1

Affiliation:

1. Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz

2. Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro

3. Hospital Santa Izabel, Salvador, Bahia

4. Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil

Abstract

ABSTRACT Chagas' disease, caused by Trypanosoma cruzi infection, is one of the main causes of death due to heart failure in Latin American countries. Benznidazole, the chemotherapeutic agent most often used for the treatment of chagasic patients, is highly toxic and has limited efficacy, especially in the chronic phase of the disease. In the present study we used a mouse model of chronic Chagas' disease to investigate the effects of benznidazole treatment during the chronic phase on disease progression. The hearts of benznidazole-treated mice had decreased parasitism and myocarditis compared to the hearts of untreated chagasic mice. Both groups of Trypanosoma cruzi -infected mice had significant alterations in their electrocardiograms compared to those of the healthy mice. However, untreated mice had significantly higher cardiac conduction disturbances than benznidazole-treated mice, including intraventricular conduction disturbances, atrioventricular blocks, and extrasystoles. The levels of antibodies against T. cruzi antigens (epimastigote extract, P 2 β, and trans -sialidase) as well as antibodies against peptides of the second extracellular loops of β 1 -adrenergic and M 2 -muscarinic cardiac receptors were also lower in the sera from benznidazole-treated mice than in the sera from untreated mice. These results demonstrate that treatment with benznidazole in the chronic phase of infection prevents the development of severe chronic cardiomyopathy, despite the lack of complete parasite eradication. In addition, our data highlight the role of parasite persistence in the development of chronic Chagas' disease and reinforce the importance of T. cruzi elimination in order to decrease or prevent the development of severe chagasic cardiomyopathy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Cited by 204 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Anticipating the side effects of benznidazole: HLA-B*35 and patch test;Enfermedades infecciosas y microbiologia clinica (English ed.);2024-06

2. Anticipating the side effects of benznidazole: HLA-B*35 and patch test;Enfermedades Infecciosas y Microbiología Clínica;2024-05

3. Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease;Frontiers in Immunology;2024-01-12

4. Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole;Asian Pacific Journal of Tropical Medicine;2023-12

5. Trypanosoma Species (Trypanosomiasis);Principles and Practice of Pediatric Infectious Diseases;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3